Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat with Carboplatin and Etoposide in Extensive Stage SCLC
NCT00702962Phase 2Terminated
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Sep 2008
- Primary completion
- Jul 2012
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in small cell lung cancer (SCLC), sponsored by Penn State Health Milton S. Hershey Medical Center. Primary endpoint: Maximum Tolerated Dose. Started Sep 2008; status: terminated.
02
Drugs
vorinostat
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00702962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00702962.